From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders
Executive Summary
Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.
You may also be interested in...
Gilead Gets Lenacapavir To EU Approval For HIV Salvage Therapy, Awaits FDA’s Call
A first-in-class capsid inhibitor, lenacapavir is a linchpin of Gilead’s long-term strategy in HIV treatment and prevention, but has faced regulatory setbacks in the US.
Gilead’s Lenacapavir On The Move Again As FDA Lifts Clinical Hold
The long-acting HIV drug’s greatest potential is for pre-exposure prophylaxis, where it would compete against ViiV’s long-acting injectable Apretude.
Gilead’s Lenacapvir May Offer Twice-Yearly HIV Salvage Therapy
A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.